Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: J Racial Ethn Health Disparities. 2020 Oct 14;8(6):1347–1355. doi: 10.1007/s40615-020-00896-3

Table 3:

Change in Morphine Milligram Equivalents (MMEs)

Bivariate Adjusted Model
β Std. Error 95% CI β Std. Error 95% CI
Intentional Injury 5.68 5.01 (−4.17, 15.53) 0.08 5.71 (−11.14, 11.29)
Age −0.37 0.18 (−0.72, −0.25)a 0.39 0.19 (0.75, −0.21)a
ISS
(Ref group: minor) Moderate (≥9 & ≤15) 10.31 5.46 (−0.42, 21.04) 6.00 5.57 (−5.00, 16.91)
Severe (≥16) 20.95 7.45 (6.30, 35.60)b 5.41 8.28 −10.87, 21.69)
Pain Rating
(Ref group: minor Moderate (>4 & ≤7) 12.74
10.75 (−8.39, 33.86) 13.40 10.55 (−7.35, 34.14)
Severe (>7) 28.46 10.28 (8.26, 48.67)b 30.76 10.14 (10.83, 50.69) b
Length of Stay
(Ref group: 1–3 days) 4–7 days 6.72 5.82 (−4.71, 18.14) 7.16 5.97 (−4.57, 18.89)
8–14 days 31.41 6.97 (17.72, 45.09)c 29.02 7.39 (14.48, 43.55) c
>14 days 22.04 10.00 (2.40, 41.67)a 23.92 10.99 (2.30, 45.54) a
Insurance
(Ref group: private) Public −6.86 8.33 (−23.23, 9.50) −3.23 8.30 (−19.47, 13.01)
Third-Party −9.22 10.93 (−30.70, 12.25) −5.16 10.99 (−26.56, 16.25)
Self-Pay −2.35 7.96 −18.00, 13.30) −3.22 8.04 (−19.10, 12.57)
Unknown 6.34 12.93 (−19.07, 31.75) 8.61 13.11 (−17.14, 34.38)
Reported substance use in past 6 months (Ref group: no reported use) 0.82 5.86 (−10.68, 12.33) −0.44 6.21 (−12.64, 11.75)
Reported overuse in past 6 months (Ref group: no reported overuse) −1.03 5.89 (−12.61, 10.55) −3.53 6.25 (−15.82, 8.75)
Year of Study
(Ref group: 2013) 2014 −0.96 6.56 (−13.85, 11.92) −1.05 6.45 (−13.74, 11.63)
2015 −1.39 6.81 (−14.77, 12.00) −5.67 6.89 (−19.21, 7.87)
2016 −15.59 7.16 (−29.66, −1.52)a 17.60 7.23 (31.80,3.40)a
2017 −10.94 17.63 (−45.58, 23.71) −19.71 18.01 (−55.11, 15.54)
a

Note: p<.05,

b

p<.01,

c

p<.001;

significant values are bolded in adjusted column